Research programme: serotonin 2C receptor agonists - Bright Minds Biosciences
Alternative Names: 5-HT2C agonists - Bright Minds BiosciencesLatest Information Update: 23 Aug 2021
At a glance
- Originator Bright Minds Biosciences
- Class Antidementias; Antiepileptic drugs; Behavioural disorder therapies; Drug withdrawal therapies
- Mechanism of Action Serotonin 2C receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Binge-eating disorder; Epilepsy; Opioid-related disorders
Most Recent Events
- 23 Aug 2021 Research programme: serotonin 2C receptor agonists - Bright Minds Biosciences is available for licensing as of 23 Aug 2021. https://brightmindsbio.com/collaborations/
- 18 Aug 2021 Pharmacodynamics data from a preclinical studies in Epilepsy released by Bright Minds Biosciences
- 16 Jun 2021 Bright Minds Biosciences plans a clinical trial for Epilepsy